GB201514760D0 - Compounds and method of use - Google Patents

Compounds and method of use

Info

Publication number
GB201514760D0
GB201514760D0 GBGB1514760.6A GB201514760A GB201514760D0 GB 201514760 D0 GB201514760 D0 GB 201514760D0 GB 201514760 A GB201514760 A GB 201514760A GB 201514760 D0 GB201514760 D0 GB 201514760D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1514760.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karus Therapeutics Ltd
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Priority to GBGB1514760.6A priority Critical patent/GB201514760D0/en
Publication of GB201514760D0 publication Critical patent/GB201514760D0/en
Priority to US15/753,353 priority patent/US10668077B2/en
Priority to JP2018508757A priority patent/JP2018523689A/ja
Priority to AU2016307885A priority patent/AU2016307885B2/en
Priority to MX2018001926A priority patent/MX2018001926A/es
Priority to PL16756763.5T priority patent/PL3337477T3/pl
Priority to PCT/GB2016/052575 priority patent/WO2017029517A1/en
Priority to HK18110947.3A priority patent/HK1251467B/en
Priority to PT167567635T priority patent/PT3337477T/pt
Priority to EP16756763.5A priority patent/EP3337477B1/en
Priority to RS20230255A priority patent/RS64095B1/sr
Priority to HRP20230376TT priority patent/HRP20230376T1/hr
Priority to FIEP16756763.5T priority patent/FI3337477T3/fi
Priority to KR1020187007564A priority patent/KR20180064387A/ko
Priority to CN201680057437.6A priority patent/CN108348505B/zh
Priority to SM20230063T priority patent/SMT202300063T1/it
Priority to CN202111104917.2A priority patent/CN113786409B/zh
Priority to DK16756763.5T priority patent/DK3337477T3/da
Priority to HUE16756763A priority patent/HUE061615T2/hu
Priority to ES16756763T priority patent/ES2939815T3/es
Priority to CA2995898A priority patent/CA2995898A1/en
Priority to LTEPPCT/GB2016/052575T priority patent/LT3337477T/lt
Priority to SI201631666T priority patent/SI3337477T1/sl
Priority to IL257499A priority patent/IL257499A/en
Priority to US16/855,758 priority patent/US11291669B2/en
Priority to US17/684,020 priority patent/US12257254B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1514760.6A 2015-08-19 2015-08-19 Compounds and method of use Ceased GB201514760D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use
SI201631666T SI3337477T1 (sl) 2015-08-19 2016-08-19 Sestavki, ki vsebujejo inhibitorje fosfoinozitid 3-kinaze in drugo antiproliferativno sredstvo
FIEP16756763.5T FI3337477T3 (fi) 2015-08-19 2016-08-19 Koostumukset, jotka käsittävät fosfoinositidi-3-kinaasin estäjiä ja toista antiproliferatiivista ainetta
CN201680057437.6A CN108348505B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
AU2016307885A AU2016307885B2 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
MX2018001926A MX2018001926A (es) 2015-08-19 2016-08-19 Composiciones que comprenden inhibidores de fosfoinositida 3-quinasa y un segundo agente antiproliferativo.
PL16756763.5T PL3337477T3 (pl) 2015-08-19 2016-08-19 Kompozycje zawierające inhibitory kinazy 3-fosfoinozytydu i drugi środek antyproliferacyjny
PCT/GB2016/052575 WO2017029517A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
HK18110947.3A HK1251467B (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
PT167567635T PT3337477T (pt) 2015-08-19 2016-08-19 Composições compreendendo inibidores de fosfoinositida-3-quinase e um segundo agente antiproliferativo
EP16756763.5A EP3337477B1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
RS20230255A RS64095B1 (sr) 2015-08-19 2016-08-19 Kompozicije koje sadrže inhibitore fosfoinozitid 3-kinaze i drugo antiproliferativno sredstvo
HRP20230376TT HRP20230376T1 (hr) 2015-08-19 2016-08-19 Sastav koji sadrži inhibitore fosfoinozitid 3-kinaze i drugo antiproliferativno sredstvo
US15/753,353 US10668077B2 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
KR1020187007564A KR20180064387A (ko) 2015-08-19 2016-08-19 포스포이노시티드 3-키나제 저해제 및 제2 항증식제를 포함하는 조성물
JP2018508757A JP2018523689A (ja) 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物
SM20230063T SMT202300063T1 (it) 2015-08-19 2016-08-19 Composizioni comprendenti inibitori della fosfoinositide 3-chinasi e un secondo agente antiproliferativo
CN202111104917.2A CN113786409B (zh) 2015-08-19 2016-08-19 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
DK16756763.5T DK3337477T3 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
HUE16756763A HUE061615T2 (hu) 2015-08-19 2016-08-19 Foszfoinozitid-3-kináz gátlószereit és második antiproliferatív hatóanyagot tartalmazó készítmények
ES16756763T ES2939815T3 (es) 2015-08-19 2016-08-19 Composiciones que contienen inhibidores de fosfositida 3-quinasa y un segundo agente antiproliferativo
CA2995898A CA2995898A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
LTEPPCT/GB2016/052575T LT3337477T (lt) 2015-08-19 2016-08-19 Kompozicijos, apimančios fosfoinozitido 3-kinazės inhibitorius ir antrąjį antiproliferacinį agentą
IL257499A IL257499A (en) 2015-08-19 2018-02-13 Compounds containing as phosphoinositide 3-kinase inhibitors and a second antiproliferative factor
US16/855,758 US11291669B2 (en) 2015-08-19 2020-04-22 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
US17/684,020 US12257254B2 (en) 2015-08-19 2022-03-01 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use

Publications (1)

Publication Number Publication Date
GB201514760D0 true GB201514760D0 (en) 2015-09-30

Family

ID=54258859

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1514760.6A Ceased GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use

Country Status (22)

Country Link
US (3) US10668077B2 (cg-RX-API-DMAC7.html)
EP (1) EP3337477B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018523689A (cg-RX-API-DMAC7.html)
KR (1) KR20180064387A (cg-RX-API-DMAC7.html)
CN (2) CN108348505B (cg-RX-API-DMAC7.html)
AU (1) AU2016307885B2 (cg-RX-API-DMAC7.html)
CA (1) CA2995898A1 (cg-RX-API-DMAC7.html)
DK (1) DK3337477T3 (cg-RX-API-DMAC7.html)
ES (1) ES2939815T3 (cg-RX-API-DMAC7.html)
FI (1) FI3337477T3 (cg-RX-API-DMAC7.html)
GB (1) GB201514760D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20230376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061615T2 (cg-RX-API-DMAC7.html)
IL (1) IL257499A (cg-RX-API-DMAC7.html)
LT (1) LT3337477T (cg-RX-API-DMAC7.html)
MX (1) MX2018001926A (cg-RX-API-DMAC7.html)
PL (1) PL3337477T3 (cg-RX-API-DMAC7.html)
PT (1) PT3337477T (cg-RX-API-DMAC7.html)
RS (1) RS64095B1 (cg-RX-API-DMAC7.html)
SI (1) SI3337477T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300063T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017029517A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2467387B1 (en) 2009-08-20 2015-01-07 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
SG11202102343QA (en) * 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20220008409A1 (en) * 2018-09-18 2022-01-13 Kabushiki Kaisha Yakult Honsha Cancer combination therapy using quinoline carboxamide derivative
HUE067967T2 (hu) * 2019-02-27 2024-12-28 Astrazeneca Ab Szarakatinib idiopátiás tüdõfibrózis kezelésében történõ alkalmazásra
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
GB201909468D0 (en) * 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) * 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1250294A (zh) * 1999-07-27 2000-04-12 邮电部武汉邮电科学研究院 以太网与同步数字体系或同步光网络融合的适配方法
HK1044277B (en) 1999-08-03 2014-02-28 Icos Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1296975A1 (en) 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4912145B2 (ja) 2004-02-26 2012-04-11 あすか製薬株式会社 ピリミジン誘導体
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
JP5302186B2 (ja) 2006-04-26 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋ阻害剤としてのピリミジン誘導体
WO2007127183A1 (en) 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
CN101501035B (zh) * 2006-08-08 2013-01-23 中外制药株式会社 作为pi3k抑制剂的嘧啶衍生物及其用途
NZ576997A (en) 2006-11-13 2012-02-24 Icos Corp Thienopyrimidinones for treatment of inflammatory disorders and cancers
AU2007334343A1 (en) 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
EP2324022A1 (de) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
AU2009299894A1 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4 -morpholino-pyrido [3, 2 -d] pyrimidines active on Pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
EP2467387B1 (en) * 2009-08-20 2015-01-07 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN105198862B (zh) 2011-07-27 2018-01-23 阿斯利康(瑞典)有限公司 取代的n‑(4‑氟‑2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
DK3003309T3 (da) * 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
JP6626437B2 (ja) 2013-10-08 2019-12-25 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514756D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Also Published As

Publication number Publication date
PL3337477T3 (pl) 2023-07-03
PT3337477T (pt) 2023-03-20
LT3337477T (lt) 2023-03-10
AU2016307885A1 (en) 2018-03-08
SI3337477T1 (sl) 2023-04-28
ES2939815T3 (es) 2023-04-27
US20230066999A1 (en) 2023-03-02
CN108348505B (zh) 2021-10-12
US20180243313A1 (en) 2018-08-30
CN113786409B (zh) 2024-04-02
CA2995898A1 (en) 2017-02-23
RS64095B1 (sr) 2023-04-28
SMT202300063T1 (it) 2023-03-17
EP3337477A1 (en) 2018-06-27
WO2017029517A1 (en) 2017-02-23
CN113786409A (zh) 2021-12-14
KR20180064387A (ko) 2018-06-14
CN108348505A (zh) 2018-07-31
MX2018001926A (es) 2018-06-19
HK1251467A1 (en) 2019-02-01
JP2018523689A (ja) 2018-08-23
US10668077B2 (en) 2020-06-02
HRP20230376T1 (hr) 2023-06-23
AU2016307885B2 (en) 2019-07-25
US11291669B2 (en) 2022-04-05
EP3337477B1 (en) 2023-02-01
US20210069200A1 (en) 2021-03-11
HUE061615T2 (hu) 2023-07-28
DK3337477T3 (en) 2023-02-20
US12257254B2 (en) 2025-03-25
FI3337477T3 (fi) 2023-04-27
IL257499A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL258768A (en) Compounds interacting with glycans and methods of use
GB201514756D0 (en) Compound and method of use
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL251996A0 (en) Converted benzohydropyrans and method of use
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
SI3218005T1 (sl) Z glikanom delujoče spojine, in postopki uporabe
PT3089971T (pt) Compostos e métodos de utilização
GB201514760D0 (en) Compounds and method of use
IL282482A (en) Variants of protoxin-II and methods of use
GB2544180B (en) Cover means and method of use thereof
GB201609786D0 (en) Compounds and method of use
IL282508A (en) Variants of protoxin-II and methods of use
PT3397364T (pt) Elementos estruturados e métodos de utilização
GB201604627D0 (en) Improved method of FT-IMS
ZA201606450B (en) Compounds and their methods of use
GB2541786B (en) Jig and method of use thereof
GB201408171D0 (en) Formulation and method of manufacture
HK40092374A (zh) 聚糖相互作用化合物及使用方法
GB201403697D0 (en) Compounds and methods of use
GB201416797D0 (en) Contianer and method of use thereof
GB201508694D0 (en) Construction apparatus and method of use thereof
GB201501257D0 (en) Cover means and method of use thereof
GB201419990D0 (en) Hprseshoe and method of manufacture
SG11201610124SA (en) Derrick assembly and method for use of same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)